公司代码：688253 公司简称：英诺特 北京英诺特生物技术股份有限公司 2024年度内部控制评价报告 北京英诺特生物技术股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 根据公司财务报告内部控制重大缺陷的认定情况，于内部控制评价报告基准日，不存在财务报告内 部控制重大缺陷，董事会认为，公司已按照企业内部控制规范体系和相关规定的要求在所有重大方面保 持了有效的财务报告内部控制。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任 ...

证券代码：688253 证券简称：英诺特 公告编号：2025-022 北京英诺特生物技术股份有限公司关于公司及子公 司近期获得资质情况的自愿披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、公司及子公司近期获得资质的基本情况 北京英诺特生物技术股份有限公司（以下简称"公司"）全资子公司英诺特 （唐山）生物技术有限公司（以下简称"唐山英诺特"）近期新取得产品资质 2 项，具体情况如下表所示： 北京英诺特生物技术股份有限公司董事会 2025 年 4 月 26 日 | 序 | 获批主体 | 产品名称 | 注册证号（备 | 发证日期 | 有效期至 | | --- | --- | --- | --- | --- | --- | | 号 | | | 案号） | | | | | | 中国产品 | | | | | 1 | 唐山英诺特 | 甲型流感病毒/乙型流感病毒/呼吸 道合胞病毒核酸检测试剂盒（PCR 荧光探针法） | 国械注准 20253400789 | 2025/4/21 | 2030/4/20 | | | | 印度尼西 ...

证券代码：688253 证券简称：英诺特 公告编号：2024-021 北京英诺特生物技术股份有限公司关于自愿披露与 专业投资机构共同投资设立产业基金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 1、本次对外投资事项目前处于筹备阶段，投资基金尚未完成工商注册 登记，尚需完成基金登记备案。如遇不可预计或不可抗力等其他因素的 影响，可能存在设立过程中因审批未获通过、登记备案未能完成等风险。 2、投资私募基金具有投资周期长、流动性较低等特点，公司作为基金 的有限合伙人承担的风险敞口以投资额为限，本次投资无保本及最低收 益的承诺。 1 / 6 投资基金名称及投资方向，与上市公司主营业务相关性：嘉兴英诺特体 外诊断产业投资并购合伙企业（有限合伙）（以工商核准名称为准）（以 下简称"标的基金"或"合伙企业"），标的基金投资领域为生物医药领 域的非上市企业，包括但不限于体外诊断、生命科学等领域的成长性企 业，且标的基金投资的部分项目与北京英诺特生物技术股份有限公司 （以下简称"公司"）主营业务具有高度强相关性。 ...

2025 年，公司以"进一步提升公司经营管理水平，强化市场竞争力，维护 公司全体股东利益，增强投资者信心"为核心，结合自身发展战略与经营情况， 制定了 2025 年度"提质增效重回报"行动方案。 公司 2024 年度"提质增效重回报"行动方案执行情况及 2025 年度"提质增 效重回报"行动方案主要举措如下： 北京英诺特生物技术股份有限公司 2025 年度"提质增效重回报"行动方案 为贯彻落实关于开展科创板上市公司"提质增效重回报"专项行动的倡议， 持续优化经营、规范治理和积极回报投资者，基于对公司未来发展前景的信心、 对公司价值的认可和切实履行社会责任，北京英诺特生物技术股份有限公司（以 下简称"公司"）于 2024 年 8 月 30 日发布了《2024 年度"提质增效重回报"行 动方案》。2024 年度，公司根据"提质增效重回报"行动方案积极开展和落实相 关工作，在提升公司经营质量、完善公司治理能力，保护投资者权益方面取得了 一定的成效。 一、聚焦经营主业，实现主营业务稳定增长 公司是一家专注于体外诊断快速诊断产品研发、生产和销售的高科技生物医 药企业，公司紧紧抓住当前社会节奏加快、分级诊疗体系不断推进、 ...

北京英诺特生物技术股份有限公司 募集资金存放与实际使用情况 审核报告 大信专审字[2025]第 34-00007 号 大信会计师事务所(特殊普通合伙) WUYIGE CERTIFIED PUBLIC ACCOUNTANTS LLP. WUYIGE Certified Public Accountants.LLP 各 1 号 Room 2206 22/F, Xueyuan International Tower 传真 No.1 Zhichun Road, Haidian Dist. Beijing, China, 100083 uninu davincna com cn 募集资金存放与实际使用情况审核报告 大信专审字[2025]第 34-00007 号 北京英诺特生物技术股份有限公司全体股东: 我们接受委托,对后附的北京英诺特生物技术股份有限公司(以下简称"贵公司")《2024 年度募集资金存放与实际使用情况的专项报告》 (以下简称"募集资金存放与实际使用情况 专项报告"进行了审核。 一、董事会的责任 地址 您可使用手机"扫一扫"或进入"注册会计师行业统一监管平台（http://acc.mof.gov.cn）" ...

证券代码：688253 证券简称：英诺特 公告编号：2025-011 北京英诺特生物技术股份有限公司 2024 年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京英诺特生物技术股份有限公司（以下简称"公司"）根据中国证券监督 管理委员会《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管 要求》《上海证券交易所科创板股票上市规则》以及《上海证券交易所科创板上 市公司自律监管指引第 1 号——规范运作》等有关规定，现将公司 2024 年度募 集资金存放与实际使用情况报告如下： 一、募集资金基本情况 为了规范募集资金的管理和使用，保护投资者权益，公司依照《中华人民共 和国公司法》《中华人民共和国证券法》《上海证券交易所科创板股票上市规则》 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等法律法 规，结合公司实际情况，制定了《北京英诺特生物技术股份有限公司募集资金使 用管理办法》（2023 年 10 月修订）（以下简称"《募集资金使用管理办法》"）， 该 ...

Dividend and Profit Distribution - The company plans to distribute a cash dividend of 5.60 CNY per 10 shares, totaling approximately 75.23 million CNY, which represents 30.48% of the net profit attributable to shareholders for the year[4]. - As of December 31, 2024, the company's accumulated undistributed profits amounted to approximately 521.18 million CNY[4]. - The total number of shares eligible for profit distribution is 134,345,456 shares after accounting for repurchased shares[4]. - The company will not issue bonus shares or conduct capital reserve transfers for the 2024 fiscal year[5]. Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the fiscal year 2023, representing a growth of 20% compared to the previous year[13]. - The company's operating revenue for 2024 reached ¥621,389,216.13, representing a 29.99% increase compared to ¥478,018,082.96 in 2023[23]. - Net profit attributable to shareholders for 2024 was ¥246,859,675.26, up 41.92% from ¥173,948,077.93 in 2023[23]. - The net profit after deducting non-recurring gains and losses for 2024 was ¥217,752,441.57, reflecting a 48.08% increase from ¥147,047,727.73 in 2023[23]. - The gross margin for the year was reported at 60%, an increase from 55% in the previous year, indicating improved operational efficiency[13]. - Basic earnings per share increased to CNY 1.81, up 41.41% from CNY 1.28 in 2023[25]. - The weighted average return on equity rose to 12.74%, an increase of 2.87 percentage points compared to 9.87% in 2023[25]. Research and Development - Research and development expenses accounted for 15.64% of operating revenue, up 4.53 percentage points from 11.11% in 2023[25]. - The company achieved a total R&D investment of ¥97,168,026.39, representing an increase of 82.95% compared to the previous year[81]. - The company has established six major technology platforms, including immunochromatography and PCR detection platforms, to enhance its R&D capabilities[43]. - The company has developed a recombinant antibody platform to ensure quality control for its antibody testing kits[77]. - The company has made significant advancements in protein purification technology, enhancing the stability of production processes[77]. Market Expansion and Strategy - The company is focusing on expanding its market presence in Southeast Asia, targeting a 30% market share within the next two years[13]. - The company plans to invest 100 million RMB in new technology development over the next year to improve diagnostic accuracy[13]. - The company aims to expand its market presence through innovative product development and strategic partnerships in the healthcare sector[50]. - The company plans to increase investment in the international market, striving to become a leading player in the global antigen detection product sector[147]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of $50 million earmarked for potential deals[160]. Compliance and Governance - The company has received a standard unqualified audit report from DaXin Accounting Firm[4]. - The board of directors has confirmed the authenticity, accuracy, and completeness of the annual report[3]. - The company is committed to ensuring timely, accurate, and complete information disclosure to maintain a positive image in the capital market[48]. - The company has not reported any major adverse effects from competition with its controlling shareholders[152]. - The company is in compliance with the corporate governance standards set by relevant regulations[152]. Risks and Challenges - The company has outlined potential risks in its management discussion and analysis section[3]. - The company faces risks related to technological upgrades, as new advancements could render existing products obsolete if not addressed timely[91]. - The company is at risk of new product development failures due to the complex and lengthy R&D process in the in vitro diagnostics industry[92]. - The rapid expansion of the company's operations may lead to management challenges if the management structure does not adapt accordingly[95]. Product Development and Innovation - New product development includes the launch of three new respiratory detection kits, which are expected to contribute an additional 200 million RMB in revenue[13]. - The company has successfully registered multiple new products, including the Helicobacter pylori antigen test kit and various biomarkers, expanding its product offerings in both domestic and international markets[44]. - The company has developed a series of respiratory testing products, including the "Full Blood Respiratory Five Item Testing Kit," which detects five pathogens associated with respiratory infections, aiding in early identification and treatment[50]. - The company has developed a combined detection kit for influenza A, influenza B, and COVID-19, which utilizes nasopharyngeal swab samples for early diagnosis and rapid screening[53]. Operational Efficiency - The company has set a target to reduce production costs by 10% through process optimization and supply chain improvements[13]. - The company employs a tiered procurement management system, categorizing raw materials into A, B, and C classes based on their impact on product performance and safety[55]. - The procurement process follows a "just-in-time" model, with departments submitting monthly requests based on safety stock and actual production needs[56]. - The company has implemented strict quality control processes and obtained certifications such as ISO 13485 and CE, ensuring high-quality products[90]. Shareholder Engagement - The company plans to hold its annual shareholder meeting on May 10, 2024, to discuss the 2023 annual report and other key proposals[154]. - The total pre-tax remuneration for executives during the reporting period amounted to 879.32 million yuan[158]. - The company has implemented a stock incentive plan, with core technical personnel receiving stock incentives during the reporting period[159].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 206,965,618.84, a decrease of 26.51% compared to CNY 281,611,655.58 in the same period last year[4] - Net profit attributable to shareholders was CNY 95,289,652.25, down 34.77% from CNY 146,085,284.93 year-on-year[4] - Basic earnings per share decreased to CNY 0.70, down 34.58% from CNY 1.07 in the same period last year[4] - Operating profit for Q1 2025 was CNY 111,740,268.98, down 35.5% from CNY 173,246,246.12 in Q1 2024[20] - Total comprehensive income for Q1 2025 was CNY 95,253,737.06, a decrease of 34.8% compared to CNY 146,148,514.28 in Q1 2024[21] Research and Development - R&D investment totaled CNY 34,547,124.87, representing a significant increase of 57.16% compared to CNY 21,982,120.56 in the previous year[4] - The proportion of R&D investment to operating revenue rose to 16.69%, an increase of 8.88 percentage points from 7.81%[4] - Research and development expenses increased to CNY 34,547,124.87 in Q1 2025, up 57.2% from CNY 21,982,120.56 in Q1 2024[19] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,273,052,624.62, reflecting a 2.74% increase from CNY 2,212,458,840.74 at the end of the previous year[5] - Total current assets as of March 31, 2025, amounted to RMB 2,066,945,047.61, an increase from RMB 1,997,548,379.07 as of December 31, 2024, reflecting a growth of approximately 3.5%[15] - The company's total assets reached RMB 2,273,052,624.62, up from RMB 2,212,458,840.74, indicating an increase of approximately 2.75%[16] - Total liabilities decreased to CNY 210,539,628.59 in Q1 2025 from CNY 219,070,375.95 in Q1 2024, a reduction of 3.4%[19] - The total liabilities increased, with accounts payable rising from RMB 90,927,479.39 to RMB 103,626,956.14, an increase of approximately 14%[16] Cash Flow - The net cash flow from operating activities was CNY 114,756,382.68, a decrease of 7.46% compared to CNY 124,003,396.25 in the previous year[4] - The company reported a cash flow from operating activities of CNY 254,550,052.12 in Q1 2025, reflecting a decline in cash inflow from operations[23] - The total cash inflow from operating activities was $258,908,022.29, compared to $271,290,079.16 in the previous period[24] - The cash and cash equivalents at the end of the period amounted to $368,810,713.21, an increase from $234,026,855.04[25] Shareholder Equity - Shareholders' equity attributable to the parent company increased by 3.47% to CNY 2,062,512,996.03 from CNY 1,993,388,464.79[5] - Total equity attributable to shareholders increased to CNY 2,062,512,996.03 in Q1 2025, up 3.5% from CNY 1,993,388,464.79 in Q1 2024[18] Other Financial Metrics - The weighted average return on net assets decreased by 2.92 percentage points to 4.70% from 7.62%[4] - The company reported non-recurring gains and losses totaling CNY 6,946,527.24 for the period[7] - The company has not reported any significant changes in the top ten shareholders or their shareholding due to securities lending activities[14] - The company’s non-current assets totaled RMB 206,107,577.01, down from RMB 214,910,461.67, reflecting a decrease of approximately 4.0%[16] - The company’s cash flow management appears to be improving, as indicated by the increase in cash and cash equivalents alongside a reduction in accounts receivable[15]

证券代码：688253 证券简称：英诺特 公告编号：2025-015 北京英诺特生物技术股份有限公司 关于增加募投项目实施内容的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 北京英诺特生物技术股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召开第二届董事会第九次会议、第二届监事会第九次会议，审议通过了《关于 增加募投项目实施内容的议案》，同意公司增加"体外诊断产品研发项目"实施 内容"新布局技术平台相关的自研、技术引进及产品研发"相关投入。 监事会发表了明确同意的意见，保荐机构华泰联合证券有限责任公司（以下 简称"华泰联合"）出具了明确的核查意见。现将有关事项公告如下： 一、募集资金基本情况 根据中国证券监督管理委员会（以下简称"中国证监会"）于 2022 年 4 月 28 日作出的《关于同意北京英诺特生物技术股份有限公司首次公开发行股票注 册的批复》（证监许可[2022]902 号），并经上海证券交易所同意，公司于 2022 年 7 月首次向社会公开发行人民币普通股（A 股）股票 ...

证券代码：688253 证券简称：英诺特 公告编号：2025-014 北京英诺特生物技术股份有限公司关于确认 2024 年 度及预计 2025 年度日常关联交易额度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 2025 年 4 月 24 日，公司召开第二届董事会第九次会议及第二届监事会第九 次会议，审议通过了《关于确认 2024 年度及预计 2025 年度日常关联交易额度的 议案》，关联董事叶逢光、张秀杰、LIN YI 回避表决，出席会议的非关联董事人 数为 6 人，不属于"出席董事会会议的非关联董事人数不足 3 人的，公司应当将 交易事项提交股东大会审议"的情况。出席会议的非关联董事一致同意该议案， 审议程序符合相关法律法规的规定。 公司独立董事专门会议审议通过该议案，并形成以下意见：全体独立董事认 为公司2024年度实施和2025年度预计的日常关联交易均属于公司与关联方之间 基于公司业务发展需要而发生的交易，交易根据自愿、平等、互利、 ...